LLM Job #14334 - generate_story_title
Conversation
You are a financial news editor. Generate informative, detailed headlines for news stories that will be used for article matching and linking.
Analyze these article titles covering the same news story and generate a single, unified headline. Source Article Titles: 1. FDA Approves First CAR T-Cell Therapy for Marginal Zone Lymphoma In the US 2. FDA Approves CAR-T Therapy for Marginal Zone Lymphoma 3. FDA nod for Breyanzi as first CAR T therapy for r/r marginal zone lymphoma 4. BMS wins fifth US approval for CAR T cell therapy Breyanzi 5. Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL) 6. FDA Approves Lisocabtagene Maraleucel for Relapsed/Refractory Marginal Zone Lymphoma Requirements: - Synthesize the core news event from all titles - Be informative and include key details (company names, specific metrics, important context) - Use neutral, professional language - Focus on the key fact or development - Include enough detail to distinguish this story from similar events - Avoid clickbait or sensationalism - Don't include source names or publication info Examples of good informative headlines: - "Tesla Reports Record Q3 Earnings of $25.2B Revenue, Beats Analyst Expectations by 8%" - "Federal Reserve Raises Interest Rates by 0.25 Percentage Points to Combat 6.4% Inflation" - "Apple Announces iPhone 16 with AI-Powered Features and Enhanced Camera System" - "Amazon Warehouse Workers in Five States Strike Over $20/Hour Minimum Wage Demand"
{
"title": "U.S. FDA Approves Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) as First and Only CAR T-Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma"
}Debug Information
▶ Structured Output Schema (JSON Schema)
{
"json_schema": {
"description": "Generated unified title for a news story",
"name": "story_title",
"schema": {
"additionalProperties": false,
"properties": {
"title": {
"description": "Informative, detailed headline with key facts and context",
"type": "string"
}
},
"required": [
"title"
],
"type": "object"
},
"strict": true
},
"type": "json_schema"
}▶ Token Usage & Performance
{
"completion_tokens": 59,
"predicted_ms": 0,
"prompt_ms": 0,
"prompt_tokens": 381,
"total_tokens": 440
}▶ Context & Parameters (Full JSON)
{
"article_count": 6,
"finish_reason": "stop",
"generated_title": "U.S. FDA Approves Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) as First and Only CAR T-Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma",
"google_story_id": 18178,
"max_tokens": 2000,
"response_format": "json_schema",
"response_format_details": {
"json_schema": {
"description": "Generated unified title for a news story",
"name": "story_title",
"schema": {
"additionalProperties": false,
"properties": {
"title": {
"description": "Informative, detailed headline with key facts and context",
"type": "string"
}
},
"required": [
"title"
],
"type": "object"
},
"strict": true
},
"type": "json_schema"
},
"temperature": 0.3
}